These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38030205)

  • 1. Proton Pump Inhibitors Ameliorate Oxaliplatin-induced Peripheral Neuropathy: Retrospective Analysis of Two Real-world Clinical Databases.
    Kobayashi A; Ikemura K; Wakai E; Kondo M; Okuda M
    Anticancer Res; 2023 Dec; 43(12):5613-5620. PubMed ID: 38030205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
    Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
    ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study.
    Yokoyama S; Nakagawa C; Hosomi K
    Support Care Cancer; 2022 Feb; 30(2):1765-1773. PubMed ID: 34595605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of the Effect of Proton Pump Inhibitors on the Anticancer Activity of Oxaliplatin.
    Hashizume J; Sato K; Nakagawa H; Harasawa H; Honda T; Kodama Y
    Cancer Diagn Progn; 2022; 2(6):620-626. PubMed ID: 36340458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.
    Teng C; Cohen J; Egger S; Blinman PL; Vardy JL
    Support Care Cancer; 2022 Jan; 30(1):33-47. PubMed ID: 34410459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of electroacupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: a single-blinded, randomized, sham-controlled trial.
    Chan K; Lui L; Lam Y; Yu K; Lau K; Lai M; Lau W; Tai L; Mak C; Bian Z; Zhong LL
    Acupunct Med; 2023 Oct; 41(5):268-283. PubMed ID: 36325677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database.
    Mine K; Kawashiri T; Inoue M; Kobayashi D; Mori K; Hiromoto S; Kudamatsu H; Uchida M; Egashira N; Koyanagi S; Ohdo S; Shimazoe T
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Kuriyama A; Endo K
    Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis.
    Wu S; Bai X; Guo C; Huang Z; Ouyang H; Huang J; Zeng W
    BMC Cancer; 2021 Nov; 21(1):1173. PubMed ID: 34727879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database.
    Inoue M; Matsumoto K; Tanaka M; Yoshida Y; Satake R; Goto F; Shimada K; Mukai R; Hasegawa S; Suzuki T; Ikesue H; Liao J; Hashida T; Nakamura M
    Sci Rep; 2021 May; 11(1):11324. PubMed ID: 34059747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
    Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
    Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats.
    Nishida K; Takeuchi K; Hosoda A; Sugano S; Morisaki E; Ohishi A; Nagasawa K
    Life Sci; 2018 Aug; 207():516-524. PubMed ID: 29981320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil extracellular traps as a unique target in the treatment of chemotherapy-induced peripheral neuropathy.
    Wang CY; Lin TT; Hu L; Xu CJ; Hu F; Wan L; Yang X; Wu XF; Zhang XT; Li Y; Yin HY; Jiang CY; Xin HL; Liu WT
    EBioMedicine; 2023 Apr; 90():104499. PubMed ID: 36870200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
    Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
    J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
    Teng C; ; Blinman PL; Vardy JL
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients.
    Sugimoto M; Takagi T; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Okubo Y; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hikichi T; Ohira H
    BMC Cancer; 2021 Dec; 21(1):1319. PubMed ID: 34886831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
    Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
    Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.